FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to pharmacology, therapy and gastroenterology, and can be used for treating ulcerative colitis. A suspension of the preparation melaxen in physiological sodium chloride solution in dose of 0.5 mg per 1 kg of body weight is administered seven times intragastrically with interval of 24 hours between injections starting from the first day of ulcerative colitis simulation to an experimental animal that underwent modelling of ulcerative colitis.
EFFECT: invention allows to prevent development of aggravations of the disease, considerably increase duration of remission, reduce probability of development of complications threatening patient’s life, increase quality of life of patients with ulcerative colitis.
1 cl, 7 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ULCERATIVE COLITIS | 2023 |
|
RU2807131C1 |
| AGENT FOR THE PREVENTION AND TREATMENT OF ULCERATE COLITIS | 2017 |
|
RU2649119C1 |
| METHOD FOR PREDICTION OF NON-SURGICAL TREATMENT FAILURE IN ULCERATIVE COLITIS | 2012 |
|
RU2501010C1 |
| METHOD FOR INDIVIDUAL SENSITIVITY TO PREPARATIONS OF 5-AMINOSALYCILIC ACID (5-ASA) IN PATIENTS WITH ULCEROUS COLITIS | 2005 |
|
RU2287819C1 |
| METHOD OF NON-INVASIVE DIAGNOSTICS OF CROHN'S DISEASE AND NON-SPECIFIC ULCERATIVE COLITIS | 2022 |
|
RU2803489C1 |
| METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2009 |
|
RU2394571C1 |
| METHOD OF MODELING ULCERATIVE DEFECTS OF THE INTESTINAL MUCOSA IN CROHN'S DISEASE ON MINIPIGS | 2022 |
|
RU2798718C1 |
| IMMUNOBIOLOGICAL AGENT BASED ON BUTYRATE AND THE METHOD FOR ITS USE FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | 2021 |
|
RU2780868C1 |
| KOBITOLIMOD FOR USE IN TREATMENT OF INFLAMMATORY BOWEL DISEASE | 2018 |
|
RU2766356C2 |
| APPLICATION OF APL PEPTIDE FOR TREATMENT OF INFLAMMATORY INTESTINAL DISEASE AND TYPE 1 DIABETES | 2009 |
|
RU2524630C2 |
